Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$573.45
-37.19-6.09%
At close: -
$555.17
-18.28-3.19%
After Hours: Apr 4, 6:56 PM EDT
Comments
Loading...
Regeneron Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:REGN | Benzinga
Regeneron Pharmaceuticals Inc has a consensus price target of $967.84 based on the ratings of 32 analysts. The high is $1300 issued by Guggenheim on August 2, 2024. The low is $165 issued by Canaccord Genuity on December 17, 2024. The 3 most-recent analyst ratings were released by JP Morgan, Baird, and Leerink Partners on March 31, 2025, February 5, 2025, and February 5, 2025, respectively. With an average price target of $864.33 between JP Morgan, Baird, and Leerink Partners, there's an implied 55.69% upside for Regeneron Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Baird
Leerink Partners
Citigroup
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Regeneron Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/31/2025 | Buy Now | 80.13% | JP Morgan | Chris Schott60% | $1100 → $1000 | Maintains | Overweight | Get Alert |
| 02/05/2025 | Buy Now | 36.72% | Baird | Brian Skorney58% | $940 → $759 | Maintains | Neutral | Get Alert |
| 02/05/2025 | Buy Now | 50.23% | Leerink Partners | David Risinger73% | $762 → $834 | Upgrade | Market Perform → Outperform | Get Alert |
| 01/28/2025 | Buy Now | 35.09% | Citigroup | Geoff Meacham61% | $795 → $750 | Maintains | Neutral | Get Alert |
| 01/27/2025 | Buy Now | 82.47% | Piper Sandler | Christopher Raymond55% | $1195 → $1013 | Maintains | Overweight | Get Alert |
| 01/16/2025 | Buy Now | 32.93% | UBS | Trung Huynh64% | $1130 → $738 | Downgrade | Buy → Neutral | Get Alert |
| 01/14/2025 | Buy Now | 43.2% | Citigroup | Geoff Meacham61% | $895 → $795 | Maintains | Neutral | Get Alert |
| 01/10/2025 | Buy Now | 62.11% | Wells Fargo | Mohit Bansal71% | $1050 → $900 | Maintains | Overweight | Get Alert |
| 01/08/2025 | Buy Now | 80.85% | Truist Securities | Srikripa Devarakonda43% | $1126 → $1004 | Maintains | Buy | Get Alert |
| 01/07/2025 | Buy Now | 92.73% | Bernstein | William Pickering41% | $1110 → $1070 | Maintains | Outperform | Get Alert |
| 12/17/2024 | Buy Now | -70.28% | Canaccord Genuity | John Newman43% | → $165 | Initiates | → Hold | Get Alert |
| 12/10/2024 | Buy Now | 1.77% | B of A Securities | Tim Anderson55% | → $565 | Reinstates | → Underperform | Get Alert |
| 11/15/2024 | Buy Now | 107.14% | Wolfe Research | Alexandria Hammond46% | → $1150 | Initiates | → Outperform | Get Alert |
| 11/14/2024 | Buy Now | 61.21% | Citigroup | Geoff Meacham61% | → $895 | Initiates | → Neutral | Get Alert |
| 11/06/2024 | Buy Now | 80.13% | Oppenheimer | Hartaj Singh47% | $1150 → $1000 | Maintains | Outperform | Get Alert |
| 11/01/2024 | Buy Now | 113.27% | Morgan Stanley | Matthew Harrison61% | $1235 → $1184 | Maintains | Overweight | Get Alert |
| 11/01/2024 | Buy Now | 118.85% | RBC Capital | Brian Abrahams50% | $1260 → $1215 | Maintains | Outperform | Get Alert |
| 11/01/2024 | Buy Now | 91.83% | Barclays | Carter Gould57% | $1080 → $1065 | Maintains | Overweight | Get Alert |
| 11/01/2024 | Buy Now | 115.25% | Piper Sandler | Christopher Raymond55% | $1242 → $1195 | Maintains | Overweight | Get Alert |
| 11/01/2024 | Buy Now | 114.35% | BMO Capital | Evan David Seigerman51% | $1300 → $1190 | Maintains | Outperform | Get Alert |
| 11/01/2024 | Buy Now | 102.82% | Truist Securities | Srikripa Devarakonda43% | $1137 → $1126 | Maintains | Buy | Get Alert |
| 10/25/2024 | Buy Now | 126.96% | RBC Capital | Brian Abrahams50% | $1260 → $1260 | Reiterates | Outperform → Outperform | Get Alert |
| 10/24/2024 | Buy Now | 111.65% | Evercore ISI Group | Cory Kasimov68% | $1250 → $1175 | Maintains | Outperform | Get Alert |
| 10/24/2024 | Buy Now | 107.14% | JP Morgan | Chris Schott60% | $1200 → $1150 | Maintains | Overweight | Get Alert |
| 10/23/2024 | Buy Now | 82.83% | Cantor Fitzgerald | Olivia Brayer58% | $1015 → $1015 | Reiterates | Neutral → Neutral | Get Alert |
| 10/23/2024 | Buy Now | 94.54% | Barclays | Carter Gould57% | $1220 → $1080 | Maintains | Overweight | Get Alert |
| 10/22/2024 | Buy Now | 89.13% | Wells Fargo | Mohit Bansal71% | $1200 → $1050 | Maintains | Overweight | Get Alert |
| 10/22/2024 | Buy Now | 126.96% | RBC Capital | Brian Abrahams50% | $1260 → $1260 | Reiterates | Outperform → Outperform | Get Alert |
| 10/16/2024 | Buy Now | 104.8% | Truist Securities | Srikripa Devarakonda43% | $1200 → $1137 | Maintains | Buy | Get Alert |
| 10/04/2024 | Buy Now | 126.96% | RBC Capital | Brian Abrahams50% | $1252 → $1260 | Maintains | Outperform | Get Alert |
| 09/24/2024 | Buy Now | 125.52% | RBC Capital | Brian Abrahams50% | $1282 → $1252 | Maintains | Outperform | Get Alert |
| 09/24/2024 | Buy Now | 134.16% | BMO Capital | Evan David Seigerman51% | $1300 → $1300 | Reiterates | Outperform → Outperform | Get Alert |
| 09/24/2024 | Buy Now | 116.15% | Truist Securities | Srikripa Devarakonda43% | $1200 → $1200 | Reiterates | Buy → Buy | Get Alert |
| 09/24/2024 | Buy Now | 94% | Leerink Partners | David Risinger73% | $1175 → $1077 | Downgrade | Outperform → Market Perform | Get Alert |
| 09/23/2024 | Buy Now | 116.15% | Wells Fargo | Mohit Bansal71% | $1200 → $1200 | Reiterates | Overweight → Overweight | Get Alert |
| 09/17/2024 | Buy Now | 130.92% | RBC Capital | Brian Abrahams50% | $1282 → $1282 | Reiterates | Outperform → Outperform | Get Alert |
| 09/16/2024 | Buy Now | 82.83% | Cantor Fitzgerald | Olivia Brayer58% | $1015 → $1015 | Reiterates | Neutral → Neutral | Get Alert |
| 09/09/2024 | Buy Now | 82.83% | Cantor Fitzgerald | Olivia Brayer58% | $1015 → $1015 | Reiterates | Neutral → Neutral | Get Alert |
| 09/09/2024 | Buy Now | 130.92% | RBC Capital | Brian Abrahams50% | $1250 → $1282 | Maintains | Outperform | Get Alert |
| 09/05/2024 | Buy Now | 125.16% | RBC Capital | Brian Abrahams50% | $1250 → $1250 | Reiterates | Outperform → Outperform | Get Alert |
| 08/23/2024 | Buy Now | 123.72% | Piper Sandler | Christopher Raymond55% | $1166 → $1242 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | 116.15% | JP Morgan | Chris Schott60% | $1150 → $1200 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | 123.36% | RBC Capital | Brian Abrahams50% | $1232 → $1240 | Maintains | Outperform | Get Alert |
| 08/02/2024 | Buy Now | 134.16% | Guggenheim | Yatin Suneja47% | $1180 → $1300 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 116.15% | Wells Fargo | Mohit Bansal71% | $1125 → $1200 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | 119.75% | Barclays | Carter Gould57% | $1200 → $1220 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | 116.15% | Truist Securities | Srikripa Devarakonda43% | $1135 → $1200 | Reiterates | Buy → Buy | Get Alert |
| 07/23/2024 | Buy Now | 116.15% | TD Cowen | Tyler Van Buren45% | $1030 → $1200 | Maintains | Buy | Get Alert |
| 07/22/2024 | Buy Now | 80.13% | Cantor Fitzgerald | Olivia Brayer58% | $925 → $1000 | Maintains | Neutral | Get Alert |
| 07/19/2024 | Buy Now | 110.03% | Piper Sandler | Christopher Raymond55% | $1000 → $1166 | Maintains | Overweight | Get Alert |
| 07/18/2024 | Buy Now | 112.55% | Guggenheim | Yatin Suneja47% | $1040 → $1180 | Maintains | Buy | Get Alert |
| 07/11/2024 | Buy Now | 112.91% | Morgan Stanley | Matthew Harrison61% | $1183 → $1182 | Maintains | Overweight | Get Alert |
| 07/10/2024 | Buy Now | 116.15% | Barclays | Carter Gould57% | $1050 → $1200 | Maintains | Overweight | Get Alert |
| 06/27/2024 | Buy Now | 107.51% | Canaccord Genuity | John Newman43% | $1152 → $1152 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 110.75% | Argus Research | Jasper Hellweg70% | $1060 → $1170 | Maintains | Buy | Get Alert |
| 06/24/2024 | Buy Now | 121.37% | RBC Capital | Brian Abrahams50% | $1229 → $1229 | Reiterates | Outperform → Outperform | Get Alert |
| 06/17/2024 | Buy Now | 107.14% | JP Morgan | Chris Schott60% | $1050 → $1150 | Maintains | Overweight | Get Alert |
| 06/12/2024 | Buy Now | 121.37% | RBC Capital | Brian Abrahams50% | $1200 → $1229 | Maintains | Outperform | Get Alert |
| 06/04/2024 | Buy Now | 116.15% | RBC Capital | Brian Abrahams50% | $1185 → $1200 | Maintains | Outperform | Get Alert |
| 05/14/2024 | Buy Now | 107.14% | Evercore ISI Group | Cory Kasimov68% | → $1150 | Initiates | → Outperform | Get Alert |
| 05/03/2024 | Buy Now | 66.62% | Cantor Fitzgerald | Olivia Brayer58% | $925 → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/24/2024 | Buy Now | 85.53% | TD Cowen | Tyler Van Buren45% | $1020 → $1030 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | 97.96% | UBS | Colin Bristow39% | $1090 → $1099 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | 66.62% | Cantor Fitzgerald | Olivia Brayer58% | → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/15/2024 | Buy Now | 66.62% | Cantor Fitzgerald | Louise Chen54% | $925 → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/12/2024 | Buy Now | 29.69% | B of A Securities | Geoff Meacham61% | $710 → $720 | Maintains | Underperform | Get Alert |
| 04/09/2024 | Buy Now | 114.17% | RBC Capital | Brian Abrahams50% | $1189 → $1189 | Reiterates | Outperform → Outperform | Get Alert |
| 04/03/2024 | Buy Now | 104.44% | Truist Securities | Robyn Karnauskas55% | $1135 → $1135 | Maintains | Buy | Get Alert |
| 03/26/2024 | Buy Now | 104.44% | Truist Securities | Robyn Karnauskas55% | $1135 → $1135 | Maintains | Buy | Get Alert |
| 03/13/2024 | Buy Now | 100.84% | Morgan Stanley | Matthew Harrison61% | $1104 → $1115 | Maintains | Overweight | Get Alert |
| 03/12/2024 | Buy Now | 102.64% | Bernstein | William Pickering41% | → $1125 | Initiates | → Outperform | Get Alert |
| 03/11/2024 | Buy Now | 102.64% | Bernstein | Aaron Gal55% | → $1125 | Initiates | → Outperform | Get Alert |
| 02/27/2024 | Buy Now | 113.27% | RBC Capital | Brian Abrahams50% | $1096 → $1184 | Maintains | Outperform | Get Alert |
| 02/06/2024 | Buy Now | 66.62% | Cantor Fitzgerald | Olivia Brayer58% | $850 → $925 | Maintains | Neutral | Get Alert |
| 02/05/2024 | Buy Now | 99.94% | RBC Capital | Brian Abrahams50% | $1076 → $1110 | Maintains | Outperform | Get Alert |
| 02/05/2024 | Buy Now | 94.9% | BMO Capital | Evan David Seigerman51% | $1055 → $1082 | Maintains | Outperform | Get Alert |
| 01/29/2024 | Buy Now | 93.82% | RBC Capital | Brian Abrahams50% | $1076 → $1076 | Reiterates | Outperform → Outperform | Get Alert |
| 01/23/2024 | Buy Now | 83.73% | Barclays | Carter Gould57% | $935 → $1020 | Maintains | Overweight | Get Alert |
| 01/12/2024 | Buy Now | 93.82% | RBC Capital | Brian Abrahams50% | → $1076 | Upgrade | Sector Perform → Outperform | Get Alert |
| 01/09/2024 | Buy Now | 53.11% | Cantor Fitzgerald | Olivia Brayer58% | $850 → $850 | Reiterates | Neutral → Neutral | Get Alert |
| 12/18/2023 | Buy Now | 88.23% | Truist Securities | Robyn Karnauskas55% | → $1045 | Reiterates | Buy → Buy | Get Alert |
| 12/06/2023 | Buy Now | 80.13% | TD Cowen | Tyler Van Buren45% | $900 → $1000 | Maintains | Outperform | Get Alert |
| 11/29/2023 | Buy Now | 88.23% | Truist Securities | Robyn Karnauskas55% | → $1045 | Reiterates | Buy → Buy | Get Alert |
| 11/28/2023 | Buy Now | 68.78% | Jefferies | Akash Tewari44% | $935 → $937 | Maintains | Buy | Get Alert |
| 11/28/2023 | Buy Now | 88.23% | Truist Securities | Robyn Karnauskas55% | → $1045 | Reiterates | Buy → Buy | Get Alert |
| 11/09/2023 | Buy Now | 44.1% | Deutsche Bank | James Shin41% | → $800 | Initiates | → Hold | Get Alert |
| 11/03/2023 | Buy Now | 61.21% | Piper Sandler | Christopher Raymond55% | $885 → $895 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | 50.77% | RBC Capital | Brian Abrahams50% | $847 → $837 | Maintains | Sector Perform | Get Alert |
| 11/03/2023 | Buy Now | 64.64% | Morgan Stanley | Matthew Harrison61% | $915 → $914 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | 71.12% | Raymond James | Dane Leone46% | → $950 | Upgrade | Market Perform → Outperform | Get Alert |
| 10/16/2023 | Buy Now | 53.11% | Cantor Fitzgerald | Alethia Young76% | $800 → $850 | Maintains | Neutral | Get Alert |
| 10/12/2023 | Buy Now | 52.57% | RBC Capital | Brian Abrahams50% | $833 → $847 | Maintains | Sector Perform | Get Alert |
| 10/11/2023 | Buy Now | 64.82% | Morgan Stanley | Matthew Harrison61% | $912 → $915 | Maintains | Overweight | Get Alert |
| 09/21/2023 | Buy Now | 44.1% | Cantor Fitzgerald | Alethia Young76% | → $800 | Reiterates | Neutral → Neutral | Get Alert |
| 09/15/2023 | Buy Now | 65.72% | Argus Research | Jasper Hellweg70% | $825 → $920 | Maintains | Buy | Get Alert |
| 09/15/2023 | Buy Now | — | WestPark Capital | — | — | Initiates | → Hold | Get Alert |
| 08/21/2023 | Buy Now | 78.68% | Canaccord Genuity | John Newman43% | $720 → $992 | Upgrade | Hold → Buy | Get Alert |
| 08/21/2023 | Buy Now | 76.52% | Wells Fargo | Mohit Bansal71% | $875 → $980 | Maintains | Overweight | Get Alert |
| 08/21/2023 | Buy Now | 88.23% | Truist Securities | Robyn Karnauskas55% | → $1045 | Reiterates | Buy → Buy | Get Alert |
| 08/21/2023 | Buy Now | 89.13% | Oppenheimer | Hartaj Singh47% | $950 → $1050 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Regeneron Pharmaceuticals (REGN) stock?
The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by JP Morgan on March 31, 2025. The analyst firm set a price target for $1000.00 expecting REGN to rise to within 12 months (a possible 80.13% upside). 67 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Regeneron Pharmaceuticals (REGN)?
The latest analyst rating for Regeneron Pharmaceuticals (NASDAQ:REGN) was provided by JP Morgan, and Regeneron Pharmaceuticals maintained their overweight rating.
When was the last upgrade for Regeneron Pharmaceuticals (REGN)?
The last upgrade for Regeneron Pharmaceuticals Inc happened on February 5, 2025 when Leerink Partners raised their price target to $834. Leerink Partners previously had a market perform for Regeneron Pharmaceuticals Inc.
When was the last downgrade for Regeneron Pharmaceuticals (REGN)?
The last downgrade for Regeneron Pharmaceuticals Inc happened on January 16, 2025 when UBS changed their price target from $1130 to $738 for Regeneron Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Regeneron Pharmaceuticals (REGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regeneron Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regeneron Pharmaceuticals was filed on March 31, 2025 so you should expect the next rating to be made available sometime around March 31, 2026.
Is the Analyst Rating Regeneron Pharmaceuticals (REGN) correct?
While ratings are subjective and will change, the latest Regeneron Pharmaceuticals (REGN) rating was a maintained with a price target of $1100.00 to $1000.00. The current price Regeneron Pharmaceuticals (REGN) is trading at is $555.17, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.